CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 270 enrolled
Drug / intervention
Galcanezumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02614287
NCT02614287Phase 3Completed
CompareCT.gov

A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine

Eli Lilly and Company·interventional·Posted Nov 25, 2015·Updated Jun 17, 2020

In Brief

A Phase 3 clinical trial evaluating Galcanezumab for Migraine. Completed, enrolled 270 participants across 27 sites in 6 countries.

Detailed Summary

The main purpose of this study is to evaluate the longer term safety of the study drug known as galcanezumab in participants with episodic or chronic migraine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesBelgium, Canada, France, Hungary, Puerto Rico, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 25, 2015
Enrollment StartNov 30, 2015
Primary CompletionMay 12, 2017
Study CompletionAug 14, 2018
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 10.6 years ago

Interventions

Galcanezumabdrug

Administered SC